Renal pathology and clinical associations in systemic sclerosis: a historical cohort study

Pantipa Tonsawan1, Komkid Talabthong1, Anucha Puapairoj2, Chingching Foocharoen1

1Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand; 2Department of Pathology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand

Background: The information guiding the treatment decision(s) for renal diseases in systemic sclerosis (SSc) is the renal pathological finding. This study aimed to evaluate the renal pathological diagnosis and its clinical feature among SSc.

Method: A historical cohort study was performed on adult Thai SSc patients who underwent renal biopsy during January 2005–December 2016. The renal pathologic findings and patient clinical characteristics were reviewed. Chi-square or Fisher’s exact test was applied to analyze the association between clinical manifestation and renal pathology.

Results: Of the 26 SSc patients identified (77% female), 46% had the diffuse cutaneous SSc subtype. The mean age at the time of biopsy was 53.2±14.4 years and median duration of disease was 2.4 years (IQR 0.5–7.0). Rapidly progressive glomerulonephritis (RPGN) was the most common renal manifestation (53.9%) followed by nephrotic syndrome (19.2%) and nephritis (11.5%). The pathological diagnosis included lupus nephritis (LN) class IV (26.9%), LN class V (19.2%), scleroderma renal crisis (SRC; 19.3%), progressive renal disease in scleroderma (7.7%), and IgA nephropathy (7.7%). The nephrotic syndrome was the most common renal feature among LN class V patients, whereas RPGN was the commonest renal presentation among LN class IV and SRC patients (p<0.001). Dialysis treatment at the time of kidney biopsy was significantly higher in SRC patients than in the other groups (p<0.001). The SRC tended to have more frequent cardiac involvement, pulmonary fibrosis, and shorter disease duration than the other groups.

Conclusion: This is the first report of renal pathologic findings in Thai SSc patients. RPGN is the commonest renal manifestation among SSc who underwent kidney biopsy; for whom LN was the most common pathological finding. Nephrotic syndrome is a clinical feature of glomerular diseases other than renal involvement in SSc.

Keywords: scleroderma, renal biopsy, glomerular disease, scleroderma renal crisis

Introduction

Systemic sclerosis (SSc) is a systemic connective tissue disease characterized by progressive skin fibrosis. SSc is classified into two types distinguished by the extent of skin involvement: limited cutaneous systemic sclerosis (lcSSc) and diffuse cutaneous systemic sclerosis (dcSSc).1,2 Renal complications are common which the prevalence was reported to be around 50%, and the prevalence was up to 60–80% per autopsy.3–5 Moreover, in some diseases it may contribute to end-stage kidney disease and mortality.6,7 The renal manifestation varies depending on the characteristics of renal abnormalities,4,8 which the spectrum of the disease include scleroderma renal crisis (SRC), normotensive renal crisis, anti-neutrophil cytoplasmic antibodies (ANCA)-associated glomerulonephritis, penicillamine-associated...
renal disease, proteinuria, microalbuminuria, and isolated reduction in glomerular filtration rate (GFR).  

SRC is a severe renal complication in SSc, which typically occurs in the first 4 years after disease onset, and more so among those diagnosed with dcSSc subset.  

The prevalence of SRC varies: 2–15% in dcSSc and 0.5–0.6% in lcSSc.  

The classic presentation of SRC is acute kidney injury (AKI), new onset of anemia, and rapid onset of accelerated hypertension.  

Proteinuria can be detected in SRC, but it is less likely to be greater than 2 g/d or in a nephrotic range.  

Kidney biopsy is an important investigation that can identify the nature of the disease especially the treatable renal condition in SSc patient; such as inflammatory glomerular disease (LN and renal involvement in systemic vasculitis), which commonly presents with an unexplained decline in GFR, proteinuria, and microscopic hematuria.  

Kidney biopsy is thus helpful for making a definite diagnosis and for guiding treatment planning.  

In Thailand, the prevalence of renal involvement in dSSc was approximately 4% and SSc overlap with other connective tissue disease was 17% of which SSc-systemic lupus erythematosus (SLE) overlap syndrome was the second most common type (16%). Renal involvement in SSc and SSc-SLE overlap syndrome has been reported in Thai SSc. However, the renal pathologic finding in SSc is limited. This study thus aimed to evaluate a renal pathological diagnosis and its clinical association among Thai SSc patients.  

Materials and methods
We conducted a historical cohort study of SSc patients over 18 years who had undergone kidney biopsy and followed up at Sirinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand, between January 2005 and December 2016. The kidney biopsy was determined by a nephrologist and the uniform indications include nephrotic syndrome, persistent proteinuria more than 500–1000 mg/day with or without hematuria, unexplained AKI, or chronic kidney disease. All renal biopsies were processed using standard techniques for light microscope and immunofluorescence and were then interpreted by renal pathologist.  

The medical charts were reviewed and included details on age, age of SSc diagnosis, sex, SSc subset, date of first detected SSc symptom, modified Rodnan skin score (mRSS), internal organ involvement, baseline comorbidities, systolic blood pressure (SBP), diastolic blood pressure (DBP), blood urea nitrogen (BUN), serum creatinine, estimated glomerular filtration rate (eGFR) by using Chronic Kidney Disease Epidemiologic (CKDEPI) equation, 24 hrs protein excretion or urine protein–creatinine ratio, urinalysis, and medical treatment.  

Operation definition
The diagnosis of scleroderma was based on the 1980 American College of Rheumatology (ACR) criteria and/or 2013 ACR/European League Against Rheumatism (EULAR) classification. Scleroderma was classified as either lcSSc or dcSSc subset as per the classification created by LeRoy et al. The definition of SSc overlap syndrome was met when the patient fulfilled the criteria for scleroderma and they had the clinical features or specific autoantibodies of a connective tissue disease.  

Pulmonary fibrosis was confirmed when interstitial fibrosis was detected by either chest radiograph or high-resolution computed tomography (HRCT) of the chest, most pronounced in the basilar portions of the lungs, or presence of Velcro crackles on auscultation not due to another cause. Cardiac involvement was defined by the detection of pericardial effusion, ejection fraction <50%, or unexplained cardiac arrhythmia. Pulmonary arterial hypertension (PAH) was defined by a mean pulmonary arterial pressure ≥25 mmHg and a pulmonary capillary wedge pressure <15 mmHg from right heart catheterization.  

Esophageal involvement was defined as the presentation with dysphagia, heartburn, and regurgitation. Intestinal involvement was defined as the clinical manifestation with diarrhea, constipation, malabsorption, chronic intestinal pseudo-obstruction, and other causes were excluded.  

AKI was defined as an increase of serum creatinine ≥0.3 mg/dL from baseline or increase of serum creatinine >1.5 times baseline that is known or presumed to have developed within 7 days serum creatinine >1.2 mg/dL at initial presentation.  

Nephritis was defined as red blood cell (RBC) in centrifuged urine >5 cells/high power field (HPF), detected dysmorphic RBC, or RBC cast with proteinuria. Nephrotic was defined as the proteinuria >3000 mg/24 hrs or spot urine protein–creatinine ratio >3000 mg of protein/gm of creatinine.  

Rapidly progressive glomerulonephritis (RPGN) was defined as the presentation with clinical syndrome characterized by nephritis with a rapid decline in GFR from a week to several months.
LN was defined by the renal pathologist according to the International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 classification. 30

Briefly, the classes were defined as follows: class I – minimal mesangial LN, class II – mesangial proliferative LN, class III – focal LN, class IV – diffuse LN, class V – membranous LN, and class VI – advanced stage LN.

SRC was defined as a renal pathology demonstrated by obliteratorive vasculopathy with an onion skin appearance of the arterioles or interlobular arteries in the chronic stage, and/or mucoid changes of the arterioles or interlobular arteries in the subacute stage, and/or fibrinoid necrosis of the arterioles or interlobular arteries in the acute stage, assuming other causes were excluded. 31

Progressive renal disease in scleroderma was defined by the non-specific abnormalities within arteries, glomerulus, and interstitium that cannot be explained by SRC or other etiologies. 15,32

Statistical analysis
The clinical characteristics were categorized as being dichotomous, polytomous, or continuous variables. The categorical data were tested for significance using the χ² or Fisher exact test (as appropriate). The respective student t-test and analysis of variance (ANOVA) were used to test for differences between means of the dichotomous and polytomous categorical data. The Wilcoxon Ranksum or Kruskal-Wallis test was applied for nonparametric testing as appropriate. Statistical tests were two-tailed and a p-value of <0.05 was considered statistically significant. All the analyses were performed using STATA version 11.2 (StataCorp., College Station, TX, USA).

Ethical considerations
The study involved human participants and was in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type, informed consent was not required. This study was approved by the Human Research Ethics Committee of Khon Kaen University (HE591128). Patient data were maintained confidentially.

Results
Twenty-six SSc patients (female to male ratio 3.3:1) who underwent kidney biopsy were included in the study. Most (46.1%) had the deSSc subset, followed by SSc overlap SLE (26.9%), and lcSSc (15.4%). Mean age and median duration of disease at the time of kidney biopsy were 53.2±14.4 years and 2.4 years (IQR 0.5–7.0), respectively. Nearly 75% of the patients had pulmonary fibrosis, and around one-third had cardiac involvement at the time of kidney biopsy. The patient characteristics are presented in Table 1.

RPGN was the commonest renal manifestation indicating that the patient underwent kidney biopsy (53.9%), followed by nephritis (19.2%), and AKI with proteinuria, and nephrotic syndrome (11.5%) each (Table 2). The renal pathology was LN class IV seven cases (26.9%), LN class V five cases (19.2%), SRC five cases (19.2%), and progressive renal disease in scleroderma two cases (7.7%) (Figure 1). The nephrotic syndrome was the most common renal presentation among LN class V patients, while RPGN was the most common renal feature among LN class IV patients, and SRC patients than in other groups (p<0.001). In addition, SRC patients tend to have more frequent cardiac involvement and pulmonary fibrosis and shorter disease duration than the other groups, albeit the differences were not statistically significant.

Discussion
Renal involvement in SSc can present with only mild proteinuria or as severe and life-threatening. Kidney biopsy is the gold standard for making a definite diagnosis of renal disease. There are, however, some limitations for performing renal biopsy among SSc patients, including patient safety, patient decision, and facilities at the medical
## Table 1 Patient characteristics by renal pathological findings

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Overall, N=26 (%)</th>
<th>LN class IV, N=7 (%)</th>
<th>LN class V, N=5 (%)</th>
<th>Scleroderma renal involvement, N=2 (%)</th>
<th>Scleroderma renal crisis, N=5 (%)</th>
<th>Other, N=7 (%)</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years): mean ± SD</td>
<td>53.2±14.4</td>
<td>50.3±14.3</td>
<td>48.6±11.2</td>
<td>62.6±2.3</td>
<td>60.1±15.3</td>
<td>51.9±17.9</td>
<td>0.616</td>
</tr>
<tr>
<td>Female</td>
<td>20 (76.9)</td>
<td>5 (71.4)</td>
<td>3 (60)</td>
<td>2 (100)</td>
<td>4 (80)</td>
<td>6 (85.7)</td>
<td>0.952</td>
</tr>
<tr>
<td>SSc subset</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.181</td>
</tr>
<tr>
<td>Diffuse cutaneous SSc</td>
<td>12 (46.1)</td>
<td>4 (57.1)</td>
<td>2 (40)</td>
<td>2 (100)</td>
<td>1 (20)</td>
<td>3 (42.9)</td>
<td></td>
</tr>
<tr>
<td>Limited cutaneous SSc</td>
<td>4 (15.4)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2 (40)</td>
<td>2 (28.6)</td>
<td></td>
</tr>
<tr>
<td>SSc overlap with other CNTD</td>
<td>10 (38.4)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2 (40)</td>
<td>1 (14.3)</td>
<td></td>
</tr>
<tr>
<td>SSc overlap PM</td>
<td>3 (11.5)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2 (40)</td>
<td>1 (14.3)</td>
<td></td>
</tr>
<tr>
<td>SSc overlap SLE</td>
<td>7 (26.9)</td>
<td>3 (42.9)</td>
<td>3 (60)</td>
<td>0</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Disease duration (years): median (IQR)</td>
<td>2.4 (0.5–7.0)</td>
<td>1.1 (0.2–12.9)</td>
<td>5.6 (2.7–7.0)</td>
<td>6.4 (3.5–9.4)</td>
<td>0.1 (0.05–0.6)</td>
<td>2.1 (0.6–8.3)</td>
<td>0.123</td>
</tr>
<tr>
<td>SSc clinical characteristics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Digital ulcer</td>
<td>6 of 24 (25)</td>
<td>1 of 6 (16.7)</td>
<td>3 (60)</td>
<td>0</td>
<td>1 of 4 (25)</td>
<td>1 (14.3)</td>
<td>0.454</td>
</tr>
<tr>
<td>Tendon friction rub</td>
<td>2 of 22 (9.1)</td>
<td>2 of 3 (4.5)</td>
<td>3 (60)</td>
<td>2 (100)</td>
<td>1 of 5 (25)</td>
<td>0</td>
<td>0.277</td>
</tr>
<tr>
<td>Hand deformity</td>
<td>7 of 20 (35)</td>
<td>1 of 5 (20)</td>
<td>2 of 3 (66.7)</td>
<td>0</td>
<td>2 of 4 (50)</td>
<td>2 (28.6)</td>
<td>0.651</td>
</tr>
<tr>
<td>Pulmonary fibrosis</td>
<td>19 (73.1)</td>
<td>4 (57.1)</td>
<td>3 (60)</td>
<td>2 (100)</td>
<td>5 (100)</td>
<td>5 (71.4)</td>
<td>0.556</td>
</tr>
<tr>
<td>PAH</td>
<td>4 (15.4)</td>
<td>2 (28.6)</td>
<td>1 (20)</td>
<td>0</td>
<td>0</td>
<td>1 (14.3)</td>
<td>0.918</td>
</tr>
<tr>
<td>Cardiac involvement</td>
<td>8 of 30 (30.8)</td>
<td>2 (28.6)</td>
<td>1 (20)</td>
<td>0</td>
<td>4 (80)</td>
<td>1 (14.3)</td>
<td>0.162</td>
</tr>
<tr>
<td>Esophageal involvement</td>
<td>9 of 19 (47.4)</td>
<td>3 of 5 (60)</td>
<td>0</td>
<td>2 (100)</td>
<td>1 of 5 (50)</td>
<td>3 (42.9)</td>
<td>0.342</td>
</tr>
<tr>
<td>Intestinal involvement</td>
<td>4 of 21 (19.1)</td>
<td>3 of 5 (60)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1 (14.3)</td>
<td>0.146</td>
</tr>
<tr>
<td>mRSS; median (IQR)</td>
<td>15 (4–18)</td>
<td>15 (10–20)</td>
<td>14 (13–15)</td>
<td>16 (16–16)</td>
<td>4 (4–4)</td>
<td>15 (4–18)</td>
<td>0.681</td>
</tr>
</tbody>
</table>

**Abbreviations**: CNTD, connective tissue disease; IQR, interquartile range; LN, lupus nephritis; mRSS, modified Rodnan skin score; PAH, pulmonary arterial hypertension; PM, polymyositis; SD, standard deviation; SSc, systemic sclerosis; SSc-PM, systemic sclerosis-polymyositis; SSc-SLE, systemic sclerosis-systemic lupus erythematosus.
Table 2 Clinical presentation and laboratory findings by renal pathological findings

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Overall, N=26 (%)</th>
<th>LN class IV, N=7 (%)</th>
<th>LN class V, N=5 (%)</th>
<th>Scleroderma renal involvement, N=2 (%)</th>
<th>Scleroderma renal crisis, N=5 (%)</th>
<th>Other, N=7 (%)</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical feature</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RPGN</td>
<td>14 (53.9)</td>
<td>6 (85.7)</td>
<td>0</td>
<td>1 (50)</td>
<td>5 (100)</td>
<td>2 (28.6)</td>
<td>0.001*</td>
</tr>
<tr>
<td>AKI with proteinuria</td>
<td>3 (11.5)</td>
<td>1 (14.3)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Nephritis</td>
<td>3 (11.5)</td>
<td>0</td>
<td>1 (20)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Nephrotic syndrome</td>
<td>5 (19.2)</td>
<td>0</td>
<td>4 (80)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Subnephrotic proteinuria</td>
<td>1 (3.9)</td>
<td>0</td>
<td>1 (50)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Dialysis at time of biopsy</td>
<td>9 of 25 (36)</td>
<td>3 (42.9)</td>
<td>0</td>
<td>0</td>
<td>5 (100)</td>
<td>1 of 6 (16.7)</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>SBP (mmHg); median (IQR)</td>
<td>130.5±23.7</td>
<td>141 (123–147)</td>
<td>122 (120–123)</td>
<td>105.5 (101–110)</td>
<td>137 (100–160)</td>
<td>137 (112–144)</td>
<td>0.161</td>
</tr>
<tr>
<td>DBP (mmHg); median (IQR)</td>
<td>74.6±14.4</td>
<td>83 (72–94)</td>
<td>70 (64–78)</td>
<td>54.5 (53–56)</td>
<td>88 (59–95)</td>
<td>73.5 (64–83)</td>
<td>0.107</td>
</tr>
<tr>
<td>Hypertension (SBP&gt;140 or DBP&gt;90)</td>
<td>9 (34.6)</td>
<td>4 (57.1)</td>
<td>0</td>
<td>0</td>
<td>3 (60)</td>
<td>2 (28.6)</td>
<td>0.214</td>
</tr>
<tr>
<td>Laboratory finding</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>eGFR (mL/min/1.73 m²); median (IQR)</td>
<td>29 (15.4–66)</td>
<td>23 (8–29)</td>
<td>121 (75–125)</td>
<td>36 (31–41)</td>
<td>11 (10–15.4)</td>
<td>52 (18–104)</td>
<td>0.002*</td>
</tr>
<tr>
<td>Proteinuria (g/day); median (IQR)</td>
<td>2.0 (1.4–3.7)</td>
<td>2.0 (1.8–3.7)</td>
<td>3.8 (3.5–4.8)</td>
<td>2.1 (1.6–2.6)</td>
<td>1.8 (1.1–3.9)</td>
<td>1.4 (0.6–2.1)</td>
<td>0.234</td>
</tr>
<tr>
<td>Urine sediment</td>
<td>11 (42.3)</td>
<td>3 (42.9)</td>
<td>2 (40)</td>
<td>0</td>
<td>1 of 4 (25)</td>
<td>5 (7.1)</td>
<td>0.530</td>
</tr>
<tr>
<td>Low complement</td>
<td>2 of 13 (15.4)</td>
<td>1 of 4 (25)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1 of 5 (20)</td>
<td>0.999</td>
</tr>
<tr>
<td>Anti-topoisomerase I positive</td>
<td>20 of 23 (87)</td>
<td>6 of 6 (100)</td>
<td>4 (80)</td>
<td>NA</td>
<td>4 (80)</td>
<td>6 (85.7)</td>
<td>0.763</td>
</tr>
</tbody>
</table>

Notes: *Statistical significance. **The diagnosis was IgA nephropathy and primary membranoproliferative glomerulonephritis, †diabetic nephropathy with acute tubular necrosis (ATN) and lupus nephritis class II with ATN, ‡IgA nephropathy and LN class II, §IgM nephropathy.

Abbreviations: AKI; acute kidney injury; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; IQR, interquartile range; LN, lupus nephritis; RPGN, rapidly progressive glomerulonephritis; SBP, systolic blood pressure.
center. These factors might have been the cause of a low rate of kidney biopsy in our study. Nevertheless, this is the first report that reviews the renal pathologic diagnosis and demonstrates the clinicopathological correlation among Thai SSc patients, who have a much greater prevalence of the dcSSc subset than in some Asian and Caucasian SSc patients.10,16,33–36

Based on the results, the renal pathology in SSc varies; we found a broad spectrum of involvements including renal involvement in scleroderma, and SSc overlap with SLE and other glomerular diseases include IgA nephropathy, IgM nephropathy, and primary MPGN. These findings indicated that glomerular diseases other than SSc overlap SLE should also be considered in the SSc patient
with proteinuria with or without AKI. A previous study revealed that chronic tubulointerstitial disease is a common renal pathologic finding in Japanese SSc patients, while glomerular disease was found in a minority. In contrast to our study, tubulointerstitial disease was not detected, possibly because of differences in the renal manifestation of the patients and indications for kidney biopsy.

LN is a common renal pathology in our SSc patients (46.2%) which reflects that the patients were SSc overlap SLE. The prevalence of SSc-SLE overlap was much higher than prior studies (6.8%, Alharbi et al and 16%, Foocharoen et al). Among these patients, 50% were diagnosed SSc overlap SLE before performing kidney biopsy. These findings suggest that some SSc overlap SLE patients did not have the extra-renal manifestation of SLE, and the diagnosis was enhanced by the kidney biopsy.

Although SRC is the most common renal complication in SSc, only 19% of our patients had pathology-diagnosed SRC. The explanation might be the low rate of renal biopsy in the patients with clinically suggestive SRC. According to our experience, SRC commonly has a low platelet count, high blood pressure, and/or hemodynamic instability (i.e., from pulmonary edema and cardiac arrhythmias), so awareness of patient safety is a limitation to perform the procedure. Moreover, SRC is a clinical diagnosis, hence only a minority of patients who had clinically suspected SRC underwent the renal biopsy. Additionally, all of the patients who had pathology consistent with SRC needed dialysis at the time of diagnosis. This finding confirms that SRC is a life-threatening renal complication and causes high morbidity and mortality in SSc; thus, treatment should be prompt for patients with clinically suspected SRC even if there is no pathology proof.

Patients who had SRC had more frequent internal organ involvement—particularly cardiac involvement and pulmonary fibrosis—and shorter disease duration than other groups of patients, albeit the differences were not statistically significant. The result suggests that physicians should monitor for SRC in SSc patients even at an early stage of disease as other internal organ involvements could occur.

Based on our findings of clinicopathological correlation, the presence of nephrotic proteinuria with inactive or bland urine sediment (urine RBC ≤5/HPF) and normal GFR indicates non-proliferative glomerulonephritis, which is common in LN class V, whereas the presence of proteinuria with active urine sediment (urine RBC >10/HPF) and reduction of GFR are commonly associated with proliferative glomerulonephritis, typically LN class IV. SRC typically presents with abruptly elevated serum creatinine, microangiopathy, and hypertension. Urinalysis may show bland or minimal proteinuria (<1 gm/d) or few microscopic hematuria, but the nephrotic range of proteinuria is rare. According to our study, 3 of 5 SRC cases had normal blood pressure, 1 had urine sediment, and 1 had nephrotic range proteinuria (2 of whom had LN class IV clinical resembling SRC without features of proliferative LN). In addition, 2 of the 5 cases diagnosed LN class V had renal clinical features compatible with proliferative LN. The results suggest that uncommon renal clinical features can be present in SSc patients. Besides, the clinical suspicion and histopathological finding might be a discordance in clinical practice. The diagnostic test for evaluation the sensitivity, specificity and predictive values can help to identify the clinical and laboratory predictors of each histopathological finding. Because of low number of each renal involvement particularly SRC in our study, the diagnostic test study is limited by statistical analysis. We do suggest including the large sample to investigate the sensitivity of clinical and laboratory findings for histopathological diagnosis of renal involvement in SSc.

The treatment of renal involvement in SSc depends on the nature of renal disease. SRC is controlled by using angiotensin-converting enzyme inhibitor (ACEI) and supportive treatment, whereas the treatment of choice in LN is steroid with or without immunosuppressive agents. Therefore, knowing the renal pathology is necessary before determining the nature of renal disease in SSc patients and as a guide for proper treatment. Although the clinical presentation, laboratory data, and serologic investigation can be used for differentiating the renal diseases, these are insufficient and unreliable evidences for making a definite accurate diagnosis in some situations. Based on our study, we would recommend performing a renal biopsy for all SSc patients with active urinary sediment with or without proteinuria >1 gm/day so as to exclude other glomerular diseases.

There are some limitations to this study. First, the results are not generalizable as the performance of renal biopsy had a selection bias. Although some patients underwent biopsy with sub-nephrotic range proteinuria or mild symptoms, the majority of renal biopsies were performed in patients with RPGN, nephrotic syndrome, or AKI, which indicated severe renal complications; thus, the rate
of renal biopsy in our study would be underestimated. Second, some data were missing as is common with retrospective studies. Third, the patients and renal outcomes were not observed, so we cannot provide the association between renal pathology and renal outcomes. Fourth, we did not investigate the association between serology and kidney histopathology because of data limitation. Nevertheless, our study provides information on the clinical features for both renal disease from SSc and renal disease from associated diseases. The results will be helpful when assessing renal disease in SSc patients and determining the most appropriate care in daily practice.

**Conclusion**

This study is the first report of renal pathologic findings in Thai SSc patients. RPGN is the most frequent renal manifestation among SSc who underwent kidney biopsy; for whom LN was the most common pathological finding. Nephrotic syndrome is a clinical feature of glomerular diseases other than renal involvement in SSc. Although the clinical and laboratory findings typically predict the glomerular inflammation and pathology, the discordance of clinicopathological association might be recognized in real practice.

**Acknowledgments**

The authors thank the Faculty of Medicine and the Scleroderma Research Group, Khon Kaen University, for its support and Mr. Bryan Roderick Hamman for assistance with the English-language presentation under the aegis of the Publication Clinic Khon Kaen University, Thailand.

**Disclosure**

The authors declare no conflicts of interest in this work.

**References**


